Subsequently, after extracting two subgroups from the main study group, the first group consisting of patients with invasive ductal carcinoma and the second group of cases having invasive lobular carcinoma, we observed significantly higher levels of PAI-1 and lower TFPI activity in patients with invasive ductal carcinoma as compared with invasive lobular cancer patients, which is in line with Lampelj et al. [24] study. This evidence concerns the gene TFPI and invasive lobular breast carcinoma.